Experimental cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT06068400
Summary
This study tested a type of immunotherapy called CAR-T for patients with multiple myeloma that had returned or stopped responding to other treatments. The goal was to see if this personalized cell therapy was safe and could help control the cancer. The trial was very small and ended early, so it was only a first look at the treatment's potential.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shenzhen Qianhai Shekou Free Trade Zone Hospital
Shenzhen, Guangdong, 518000, China
Conditions
Explore the condition pages connected to this study.